Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer - Wikidata - awgldk - TriplyDB

Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer

Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer

http://www.wikidata.org/entity/Q35180757

about

Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials Management of the Positive Axilla in 2017 Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.Targeting and limiting surgery for patients with node-positive breast cancer.Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (All Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy.Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.Surgical considerations in patients receiving neoadjuvant systemic therapy.Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment.Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.Breast Cancer Clinical Trials: Past Half Century Moving Forward Advancing Patient Outcomes.β2-AR signaling controls trastuzumab resistance-dependent pathway.Trends and controversies in multidisciplinary care of the patient with breast cancer.Patterns of Care in the Administration of Neo-adjuvant Chemotherapy for Breast Cancer. A Population-Based Study.Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis.Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.Targeted axillary dissection after neoadjuvant therapy in breast cancer.Is there a role for sentinel node biopsy in the pre-operative ultrasound positive axilla?Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Therapy (ILINA Trial) : A New Tool to Guide the Excision of the Clipped Node After Neoadjuvant Treatment.Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype.Ultrasound-Guided Restaging and Localization of Axillary Lymph Nodes After Neoadjuvant Chemotherapy for Guidance of Axillary Surgery in Breast Cancer Patients: Experience with Activated Charcoal.MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.Localizing the Clipped Node in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Early Learning Experience and Challenges.The Impact of Neoadjuvant Treatment on Surgical Options and Outcomes.Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer.Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.

P2860

Q28072923-6E4F0C23-3575-484D-BD22-B819305CF5F9 Q33752466-A42DBBC7-8B9E-462D-8DF4-7945A566159E Q34158197-8D729A88-A3DE-4A37-AAD6-359E1744EBF1 Q35673614-8538AC31-383E-42F5-9327-46CCA361BA3E Q36166625-63B5EF6D-A19E-4757-9610-F1DDDED0EFEF Q36245392-7F2CCCA5-D601-47AB-9CED-A7094656067D Q36649784-824F0A7E-0A72-4588-9FE2-A99B8E80C624 Q36838312-87B1BD1D-9632-4F05-8BD5-316267CCBE50 Q37065621-8C2DE4E4-FED9-4D49-A885-805F79326DDE Q37460276-15D09B27-85E9-44E2-AFC2-1F5607280641 Q37992692-90861994-7EAE-4134-9498-DADEB0120865 Q38409756-131CA72B-FA3D-4AF2-8DCB-FAAA317E433A Q38761471-8F611B2A-2E27-47A5-A166-7C780CA48E24 Q38785778-93C4CAC2-E94F-405B-BB62-00C70BF049B3 Q38830282-1A2D249A-B7E3-4DED-8E27-26468D38FD87 Q38882550-91BAAF53-DEAD-4947-B9D1-E66EF207A803 Q38896403-3EE4EC81-C500-4516-A899-D40EAF31C87F Q39119467-C4CF06E8-595B-4FEF-90E5-C3F08AF88D0F Q39946087-645284AC-440C-4DE3-B254-E1E137524845 Q41396972-D45C0616-7DF5-4608-A571-966B2335E622 Q44382397-2BF53A9E-D236-46C4-A76A-B6A16492669F Q47838863-1EB2982D-E538-4A23-8142-0C80EC87C5C3 Q48169163-158C8D9F-7BC9-4951-B6A3-DD3946923911 Q48303250-80577D83-909D-4C43-9324-CA6233807A35 Q49351278-0DCA5F4A-8134-4AEE-A147-E452656D5013 Q49580314-4FB7DF69-A138-4005-B841-157DE01A3891 Q49580516-BFCF55D9-9F33-4D5E-A06F-D603912337E2 Q50038885-32EFA9B6-5F19-4DBD-B5C2-076075798421 Q50052437-7F1FEE57-3857-4302-A21A-59C1D41CAF38 Q50431199-FD5CF436-2941-4FDF-8125-132C62593460 Q53075430-E8046723-7FE7-4F03-AB5B-43D13717032C Q53095851-1A153400-7EB6-4332-8AF6-FA9FC6824FE5 Q54187504-BE8C40A2-55BC-4CC1-ABD1-44D6F996685B

P2860

Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer

http://www.wikidata.org/entity/Q35180757

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Cytologically proven axillary ...... or HER2-positive breast cancer

@ast

Cytologically proven axillary ...... or HER2-positive breast cancer

@en

type

label

Cytologically proven axillary ...... or HER2-positive breast cancer

@ast

Cytologically proven axillary ...... or HER2-positive breast cancer

@en

prefLabel

Cytologically proven axillary ...... or HER2-positive breast cancer

@ast

Cytologically proven axillary ...... or HER2-positive breast cancer

@en

P1433

Q35180757-0173937C-BC43-4B4F-85A5-1F78547E8951

P1476

Q35180757-E4B1548A-B04D-4AFC-92EC-FB51C95533F0

P2093

Q35180757-0A532FC8-C623-4881-B244-882EC7F78B6E

Q35180757-6E5F7D22-8678-446A-9B46-CCB0E5BE2C55

Q35180757-9640C7E8-06F4-4608-A0D1-466DC9EF929D

Q35180757-A0A71CAB-E583-44F9-AACF-988C97084CF7

Q35180757-A82C2D69-E19D-4DFC-A3E0-67BF3C03CC3C

Q35180757-BC65A00A-7DA7-4D7B-BB41-AEEA763BF325

Q35180757-CE9E49F0-D487-4D0B-9119-C3084B24A81D

Q35180757-DDA9D9F0-DC6D-4403-9308-6F4AE2E1C14B

Q35180757-F5AD85CF-F42F-44E7-A25A-F36F1368571B

P2860

Q35180757-19BAAE38-6E1E-4F5E-8D92-12E9704BDD62

Q35180757-281D9E12-E9C2-47A5-A0B7-B0264E10CB93

Q35180757-36AED8FD-249B-496A-BA41-3475CA117835

Q35180757-4D71B89C-250F-46C8-8909-DCEDF9AFD895

Q35180757-AE746712-6DD2-452E-B4EA-BF034AD62113

Q35180757-DE1BE766-CA01-4912-AA78-C32BC01878A8

P304

Q35180757-40C7B635-71B9-4CCE-9800-C6D547B6BDFF

P31

Q35180757-03C29E8A-20A1-496D-BC6E-749AEECCC972

P356

Q35180757-5D8CA046-F2C2-4253-9920-F908D2B2A673

P407

Q35180757-9E772D4D-22C4-4616-A549-02352524FC40

P433

Q35180757-2A078315-87D0-4936-B813-B0756E4EFAE0

P478

Q35180757-2708EE94-5D71-4F1C-984F-EDFCD1FB0FD8

P50

Q35180757-EA81FDE3-E3FC-46D0-8FDF-5A26023964E8

P577

Q35180757-541460CC-2CCF-46CC-926E-A7C4AD735DA2

P5875

Q35180757-FD946EAA-C7CB-4A36-9718-46ADEC7C10CB

P698

Q35180757-DA498364-2908-4216-8347-AE01F513A571

P921

Q35180757-C41D7888-6B9B-4BAA-8AD8-0511C07C47E2

Q35180757-F571D4EA-69DE-4CA5-9DDF-B9216D3EC2A4

P932

Q35180757-6F36B368-9A5F-4DB9-84BE-2692B132AB36

P356

P1433

P1476

Cytologically proven axillary ...... or HER2-positive breast cancer

@en

P2093

Aman U Buzdar

http://www.w3.org/2001/XMLSchema#string

Anthony Lucci

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Mittendorf

http://www.w3.org/2001/XMLSchema#string

Gildy V Babiera

http://www.w3.org/2001/XMLSchema#string

Henry M Kuerer

http://www.w3.org/2001/XMLSchema#string

Huong T Le-Petross

http://www.w3.org/2001/XMLSchema#string

Kelly K Hunt

http://www.w3.org/2001/XMLSchema#string

Laura S Dominici

http://www.w3.org/2001/XMLSchema#string

Viviana M Negron Gonzalez

http://www.w3.org/2001/XMLSchema#string

P2860

Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.

Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies.

The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer.

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

P304

2884-2889

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25152

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Funda Meric-Bernstam

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44688956

http://www.w3.org/2001/XMLSchema#string

P698

20564395

http://www.w3.org/2001/XMLSchema#string

P921

P932

4361091

http://www.w3.org/2001/XMLSchema#string